0001104659-23-082549.txt : 20230720 0001104659-23-082549.hdr.sgml : 20230720 20230720070524 ACCESSION NUMBER: 0001104659-23-082549 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230718 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TREVENA INC CENTRAL INDEX KEY: 0001429560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36193 FILM NUMBER: 231098066 BUSINESS ADDRESS: STREET 1: 955 CHESTERBROOK BOULEVARD STREET 2: SUITE 110 CITY: CHESTERBROOK STATE: PA ZIP: 19087 BUSINESS PHONE: 6103548840 MAIL ADDRESS: STREET 1: 955 CHESTERBROOK BOULEVARD STREET 2: SUITE 110 CITY: CHESTERBROOK STATE: PA ZIP: 19087 8-K 1 tm2321671d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 18, 2023

TREVENA, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-36193		26-1469215
(Commission File No.)		(IRS Employer Identification No.)

955 Chesterbrook Boulevard, Suite 110

Chesterbrook, PA 19087

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (610) 354-8840

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		TRVN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 18, 2023, the Board of Directors (the “Board”) of Trevena, Inc. (the “Company”) appointed Dr. Mark Corrigan as a director of the Company, effective July 18, 2023.

Dr. Corrigan is a highly successful pharmaceutical executive with more than 30 years of industry experience. Dr. Corrigan has served as Chief Executive Officer of Tremeau Pharmaceuticals, a pharmaceutical company that Dr. Corrigan co-founded, since January 2023. Dr. Corrigan has also served on the Board of Directors of Tremeau since April 2017. Prior to his appointment as CEO of Tremeau, Dr. Corrigan served as Chief Executive Officer of Correvio Pharma Corp, a specialty pharmaceutical company, and, prior to that, as President of Research & Development of Tremeau. Dr. Corrigan serves as Chairman of the Board of Directors of Elios Therapeutics and as a member of the Board of Directors of Nabriva Therapeutics and Wave Life Sciences. In addition, Dr. Corrigan is currently a visiting professor in the Department of Psychiatry at Brigham and Women’s Hospital in Boston, MA.

Dr. Corrigan previously served on the Board of Directors of Cubist Pharmaceuticals, a hospital acute care focused company, prior to its approximately $9.5 billion acquisition by Merck. He also served as a member of the Board of Directors and Chair of the Scientific Advisory Committee of Avanir Pharmaceuticals, a CNS focused company, prior to its approximately $3.5 billion acquisition by Otsuka Pharmaceutical. Dr. Corrigan holds a B.A. and M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.

Upon his appointment to the Board, Dr. Corrigan became entitled to receive benefits under the Company’s Non-Employee Director Compensation Policy, including an annual cash retainer of $45,000. Dr. Corrigan will also be entitled to reimbursement of his expenses incurred in connection with the performance of his services as a director.

In addition, Dr. Corrigan will be entitled to receive an annual grant of nonstatutory stock options under the Company’s 2023 Equity Incentive Plan. On July 18, 2023, Dr. Corrigan received an initial grant of nonstatutory stock options to acquire 34,250 shares of the Company’s common stock, which will vest quarterly over a three-year period, subject to Dr. Corrigan’s continued service through each applicable vesting date. In the event Dr. Corrigan is appointed to serve on any committees of the Board, Dr. Corrigan will be entitled to the additional compensation for committee service as set forth in the Company’s Non-Employee Director Compensation Policy.

There is no understanding or arrangement between Dr. Corrigan and any other person or entity pursuant to which Dr. Corrigan was appointed as a director of the Company. There is no family relationship between Dr. Corrigan and any director or executive officer. There are no transactions to which the Company is or was a participant and in which Dr. Corrigan has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

The full text of the press release announcing Dr. Corrigan’s appointment is furnished as Exhibit 99.1 to this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any other filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Number		Description
99.1		Press Release dated July 20, 2023

104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TREVENA, INC.

Date: July 20, 2023	By:	/s/ Barry Shin
		Barry Shin
		Senior Vice President & Chief Financial Officer

EX-99.1 2 tm2321671d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

CHESTERBROOK, Pa., July 20, 2023, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company’s Board of Directors, effective July 18 2023.

“We are pleased to welcome Mark to Trevena’s Board of Directors,” said Carrie Bourdow, Trevena’s President and CEO. “Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise. He will be an invaluable member of the Board and guide to the management team as we continue to execute on our corporate strategy and advance our novel S1P receptor modulator, TRV045, for the potential treatment of epilepsy and chronic pain.”

“This is a very exciting time for Trevena, a company with the proven ability to take a novel product from initial discovery through development, approval and launch,” said Dr. Corrigan. “Trevena has an innovative pipeline of wholly owned CNS assets, and I am particularly excited about the many near-term milestones, including data readouts from the two proof-of-concept studies for TRV045.”

Dr. Corrigan is a highly successful pharmaceutical executive with more than 30 years of industry experience. Dr. Corrigan has served as Chief Executive Officer of Tremeau Pharmaceuticals, a pharmaceutical company that Dr. Corrigan co-founded, since January 2023. Dr. Corrigan has also served on the Board of Directors of Tremeau since April 2017. Prior to his appointment as CEO of Tremeau, Dr. Corrigan served as Chief Executive Officer of Correvio Pharma Corp, a specialty pharmaceutical company, and prior to that as President of Research & Development of Tremeau. Dr. Corrigan serves as Chairman of the Board of Directors of Elios Therapeutics and as a member of the Board of Directors of Nabriva Therapeutics and Wave Life Sciences. In addition, Dr. Corrigan is currently a visiting professor in the Department of Psychiatry at Brigham and Women’s Hospital in Boston, MA.

Dr. Corrigan previously served on the Board of Directors of Cubist Pharmaceuticals, a hospital acute care focused company, prior to its approximately $9.5 billion acquisition by Merck. He also served as a member of the Board of Directors and Chair of the Scientific Advisory Committee of Avanir Pharmaceuticals, a CNS focused company, prior to its approximately $3.5 billion acquisition by Otsuka Pharmaceutical. Dr. Corrigan holds a B.A. and M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

For more information, please visit www.Trevena.com

About TRV045

TRV045 is a novel, selective sphingosine-1-phosphate subtype 1 (S1P₁) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy.

S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability.

Trevena's discovery efforts have identified a family of compounds that are highly selective for the S1P₁ receptor. TRV045 reversed thermal hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function at or above pharmacologically active doses in nonclinical studies. TRV045 is an investigational product and is not yet approved by the FDA.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates and approved product, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of discussions with FDA; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

For more information, please contact:

Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576

Company Contact:

Bob Yoder
SVP and Chief Business Officer
Trevena, Inc.
(610) 354-8840

EX-101.SCH 3 trvn-20230718.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 trvn-20230718_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 trvn-20230718_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jul. 18, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 18, 2023
Entity File Number	001-36193
Entity Registrant Name	TREVENA, INC.
Entity Central Index Key	0001429560
Entity Tax Identification Number	26-1469215
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	955 Chesterbrook Boulevard
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Chesterbrook
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	610
Local Phone Number	354-8840
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	TRVN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm2321671d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001429560 2023-07-18 2023-07-18 iso4217:USD shares iso4217:USD shares 0001429560 false 8-K 2023-07-18 TREVENA, INC. DE 001-36193 26-1469215 955 Chesterbrook Boulevard Suite 110 Chesterbrook PA 19087 610 354-8840 false false false false Common Stock, $0.001 par value TRVN NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://trevenainc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2321671d1_8k.htm tm2321671d1_ex99-1.htm trvn-20230718.xsd trvn-20230718_lab.xml trvn-20230718_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2321671d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2321671d1_8k.htm" ] }, "labelLink": { "local": [ "trvn-20230718_lab.xml" ] }, "presentationLink": { "local": [ "trvn-20230718_pre.xml" ] }, "schema": { "local": [ "trvn-20230718.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "trvn", "nsuri": "http://trevenainc.com/20230718", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2321671d1_8k.htm", "contextRef": "AsOf2023-07-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://trevenainc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2321671d1_8k.htm", "contextRef": "AsOf2023-07-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://trevenainc.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-082549-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-082549-xbrl.zip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